(R)-Fadrozole
Modify Date: 2025-08-27 17:39:50
(R)-Fadrozole structure
|
Common Name | (R)-Fadrozole | ||
|---|---|---|---|---|
| CAS Number | 102676-87-9 | Molecular Weight | 223.27 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H13N3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of (R)-Fadrozole(R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor[1]. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2]. |
| Name | (R)-Fadrozole |
|---|
| Description | (R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor[1]. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2]. |
|---|---|
| Related Catalog | |
| Target |
pIC50: 6.17 (human placental aromatase) |
| In Vitro | The (-)-enantiomer with the S-absolute configuration was responsible for the high aromatase inhibitory activity of (R)-Fadrozole[1]. |
| In Vivo | (R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) and (S)-fadrozole similarly decreases plasma aldosterone levels, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole[2]. (R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) effectively reverses preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect[2]. Animal Model: SHHF rats[2] Dosage: 0.24 and 1.2 mg/kg Administration: Daily; oral Result: Decreased plasma aldosterone levels and reversed preexistent left ventricular interstitial fibrosis. |
| References |
| Molecular Formula | C14H13N3 |
|---|---|
| Molecular Weight | 223.27 |
| Hazard Codes | Xi |
|---|